2015, Clinical Trials, DEA and Topical

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2015

Clinical Trials

DEA

Topical

US Hemp Roundtable: Statement On The Status of Hemp Derived CBD Under Federal Law

Cannabis Law Report

JANUARY 11, 2019

Accordingly, the Drug Enforcement Administration (DEA) no longer has any claim to interfere with the interstate commerce of hemp products, so as long as the THC level is at or below 0.3%. While the DEA is now officially out of the hemp regulation business, the U.S. The FDA’s position on CBD is unsettled and unsupported by law.

Hemp

Hemp CBD Law Seed-To-Sale

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Lancet Neurol Dec 23 2015.

Extraction

Extraction Pharmaceutical CBD Epilepsy

Medical Cannabis Brief

US Hemp Roundtable: Statement On The Status of Hemp Derived CBD Under Federal Law

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Stay Connected